ICTM logo
ESMO Congress 2017

01 September 2017

Next Friday marks the beginning of the ESMO Congress 2017, where MRC Clinical Trials Unit at UCL will be presenting results from prostate and ovarian cancer trials.

The ESMO Congress brings together a large number of oncology professionals from across Europe. It will take place from Friday 8 September to Tuesday 12 September, in Madrid, Spain.

 

Details of the MRC CTU at UCL presentations taking place at ESMO 2017 are shown below.

Day

Session (local time)

Session Type

Title

Author(s)

Location

08 September 2017

14:00 - 14:12

Paper Session: Genitourinary tumours, prostate

Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE

M. Sydes et al.

Sevilla Auditorium

08 September 2017

14:00 - 15:30

Primary and secondary prevention of cancer: Where do we stand

Aspirin for prevention and adjuvant treatment of cancer

R. Langley

Cartagena Auditorium

08 September 2017

16:00 - 16:12

Paper Session: Gynaecological Cancers

ICON8: A GCIG Phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line Epithelial Ovarian/ Fallopian Tube/ Primary Peritoneal Carcinoma (EOC) treatment: Results of Primary Progression- Free Survival (PFS) analysis

A. Clamp et al.

Cordoba Auditorium

09 September 2017

13:15 - 14:15

Poster Display Session

ICON7: ovarian cancer, platinum second-line chemotherapy and overall survival

A. Cook et al.

Hall 8

10 September 2017

09:15 - 10:30

Poster Discussion Session: Genitourinary tumours, prostate

What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis

C. Vale et al.

Bilbao Auditorium

10 September 2017

09:15 - 10:30

Poster Discussion Session: Genitourinary tumours, prostate

Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE

N. James et al.

Bilbao Auditorium